Physician profile
Lee Ann E Hritz
NPI 1083920060
$7,725.93
in general payments reported to CMS, 2019-2025
31 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,695 · 2022: $1,742 · 2023: $2,362 · 2024: $1,367 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,098 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,097.79 |
| Education | $191.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,756.80 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $957.63 | 2021-2024 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $670.96 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $602.80 | 2021-2025 | Stelara, Tremfya |
| Ardelyx, INC. | $494.71 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $348.24 | 2021-2023 | |
| Qol Medical, LLC | $347.36 | 2021-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $233.93 | 2021-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $208.92 | 2021-2024 | Ocaliva |
| Celgene Corporation | $192.00 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $110.46 | 2021-2024 | Dificid |
| Redhill Biopharma INC. | $92.68 | 2021-2022 | |
| Gilead Sciences, INC. | $87.73 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $87.43 | 2024-2025 | Iqirvo |
| Daiichi Sankyo INC. | $70.91 | 2022-2023 | Injectafer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $66.85 | 2021 | |
| Phathom Pharmaceuticals, INC. | $61.96 | 2024 | Voquezna |
| Organon LLC | $43.30 | 2024 | |
| Smith+Nephew, INC. | $42.10 | 2021 | |
| Pfizer INC. | $36.20 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $31.31 | 2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.95 | 2023-2024 | Cyltezo |
| Madrigal Pharmaceuticals | $24.12 | 2024 | Resmetirom |
| Aimmune Therapeutics, INC. | $18.09 | 2024 | |
| Celltrion USA INC. | $16.56 | 2024 | Zymfentra |
| Braintree Laboratories, INC. | $16.36 | 2024 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $16.21 | 2021 | |
| Novo Nordisk INC | $15.59 | 2023 | |
| Csl Behring | $15.56 | 2022 | |
| Horizon Therapeutics Plc | $14.65 | 2022 | |
| Lilly USA, LLC | $14.56 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Ann Hritz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.